Management of opioid-induced pruritus: a role for 5-HT3 antagonists?
| Autor: | G J Hobbs, K Kyriakides, S. K. Hussain |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male Adolescent medicine.medical_treatment Placebo Fentanyl law.invention Ondansetron Double-Blind Method Randomized controlled trial law medicine Humans Prospective Studies Alfentanil skin and connective tissue diseases Prospective cohort study Saline Aged business.industry Incidence (epidemiology) Pruritus Antagonist Middle Aged Analgesics Opioid Anesthesiology and Pain Medicine Opioid Anesthesia Itching Female Drug Eruptions Serotonin Antagonists medicine.symptom business medicine.drug |
| Zdroj: | British Journal of Anaesthesia. 82:439-441 |
| ISSN: | 0007-0912 |
| DOI: | 10.1093/bja/82.3.439 |
| Popis: | We have evaluated the efficacy of ondansetron in the prevention of opioid-induced pruritus in a prospective, randomized, double-blind, placebo-controlled study. Using a 'human model' of opioid-induced pruritus, 80 ASA I-II patients about to undergo routine surgery were given either ondansetron 4 mg i.v. or 0.9% saline i.v. (40 in each group), 30 min before alfentanil 10 mg kg-1 i.v. During the following 5 min, patients were observed for signs of perinasal scratching and at 5 min were asked about symptoms of pruritus. The study was then terminated and anaesthesia was induced. There was a significant reduction in the incidence of scratching in patients receiving ondansetron compared with placebo (42.5% vs 70%, respectively, P = 0.013). The incidence of itching in the ondansetron group was less than that in the placebo group but this was not statistically significant (30% vs 42.5%, respectively, P = 0.245). We conclude that the 5-HT3 antagonist ondansetron may have a role in the management of opioid-induced pruritus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|